Alcohol De-addiction

Treatment of substance misuse is a multistage process integrating physical, psychological and social interventions. These should run concurrently, not consecutively, and must be acceptable to the individual and sensitive to the specific needs of the elderly.

Five sequential components: (i) identification of the case, (ii) examination of the patient's attitude and motivation, (iii) detoxification where physical dependence exists, (iv) treatment of perpetuating comorbidity (especially depression), and (v) psychological rehabilitation and social intervention.

Nihilism is the enemy. Pessimistic attitudes held by professionals and carers are frequently shared by the patient — a fatalistic resignation to a life of substance misuse, particularly in long-term users, while more recent-onset users express greater motivation for treatment.

Clinical observation allied to sensitive yet persistent enquiry, supported by routine use of standardised screening tools (CAGE, SMAST-G, MAST-9) to focus clinical impression accurately.

Patients rarely present complaining of alcohol; they present with associated physical problems — falls, delirium, malnutrition, liver disease, poor diabetes control, or unexplained functional decline.

Examine the patient's attitude to their drinking. Exploration of the risks and discussion of potential avenues for change helps establish or reinforce motivation to change.

Assess comorbidity and polysubstance use. Always calculate the total benzodiazepine or opioid dose using class-specific equivalence charts, because cross-tolerance exists within drug classes and also between alcohol and benzodiazepines — widely exploited during detoxification, but causes dependence to be missed if overlooked.

Assess the social matrix. Housing, and a social network consisting mainly of substance misusers, perpetuates the problem and must be examined for opportunities to change.

Drugs causing significant physical dependence necessitate a detoxification regimen. In older adults, safe withdrawal may take weeks to months, compared with days to weeks in younger adults — the single most important age-specific point.

The withdrawal period in the elderly is far more likely to be complicated by confusion (delirium) than in younger adults. Withdrawal may also present with psychotic episodes with hallucinations and delusions, nocturnal restlessness, paradoxical excitement, anxiety and increased suicide risk.

Setting. Where severe dependency is suspected or rapid withdrawal is necessary, detoxification is best conducted in an inpatient setting. Rapid detoxification risks breakthrough withdrawal symptoms and may be complicated by convulsions.

Supportive measures: parenteral thiamine before any glucose load (to prevent Wernicke's encephalopathy), correction of electrolytes and magnesium, hydration, nutrition, and a quiet, well-lit, orientating environment with delirium precautions.

Benzodiazepine-assisted withdrawal uses the alcohol–benzodiazepine cross-tolerance principle; in older adults a shorter-acting agent (e.g. lorazepam) is preferred where hepatic impairment exists, with symptom-triggered rather than fixed-dose regimens to limit total exposure.

Naltrexone has some supporting evidence in older adults. There is insufficient evidence to endorse disulfiram, acamprosate or topiramate in this age group. Disulfiram is particularly hazardous in the elderly because of cardiovascular comorbidity.

Treat comorbid depression adequately, since it perpetuates the disorder; do not treat anxiety in the recovering drinker with benzodiazepines, given cross-dependence risk.

After detoxification, rehabilitation is necessary to address the issues behind the substance use and to foster future coping strategies. Detoxification alone is not treatment.

Outcomes equal those in younger patients. Janik and Dunham compared over 3,000 people aged over 60 with younger entrants to alcohol treatment programmes: at six months there were no differences between the groups — a powerful argument against therapeutic nihilism.

Age-specific programmes improve retention. Kofoed et al. showed greater retention in an age-specific outpatient group focused on socialisation and minimal confrontation, compared with older patients in a mixed-age group — although at one-year follow-up the effect was lost.

Low-confrontation models are superior in the elderly. Kashner et al. found elders in a confrontational programme had half the abstinence rate at one year compared with a programme promoting self-esteem, tolerance and peer relationships. Confrontation, traditionally regarded as fundamental to overcoming denial, is inappropriate for older adults.

Effective components: models encouraging development of social networks with self-management skills; behavioural approaches including cue identification and avoidance; and variants of the AA 12-step model tailored to elders (reported with varying success).

Psychosocial approaches must be routine — support groups, AA, individual counselling and family intervention.

Address the psychosocial aetiology. Four theories guide intervention: social control theory (weak social bonds), social learning theory (role models), behavioural economics / behavioural choice theory (lack of alternative rewards — educational, social, physical activities), and stress and coping theory (substance use as avoidance coping). Providing alternative rewarding activities is therapeutic, not merely recreational.

Aftercare may be delivered through generic old-age psychiatry services or specialist drug services, depending on which best meets the individual's needs. Avoid drugs with dependence potential in ongoing prescribing where practical.

Standard pharmacotherapy — current consensus. Three medications are FDA-approved for AUD — acamprosate, naltrexone and disulfiram — with gabapentin and topiramate as additional evidence-based options; naltrexone is also available as an extended-release intramuscular formulation. Acamprosate and oral or XR naltrexone are the preferred pharmacologic treatments for moderate or severe AUD, and head-to-head trials have not consistently shown either superior. This diverges from the textbook's "insufficient evidence for acamprosate."

Adherence and pill burden matter. Acamprosate requires two tablets three times daily, oral naltrexone is once daily, and XR naltrexone is given every 28 days — XR naltrexone is therefore attractive in older adults with polypharmacy or poor adherence.

More options in Europe. Baclofen, nalmefene and sodium oxybate are approved in some European regions; naltrexone and nalmefene are safe and effective particularly in patients not yet abstinent, and targeted (as-needed) naltrexone significantly reduces drinks per drinking day.

GLP-1 receptor agonists — the major emerging development. A phase 2 double-blind RCT of once-weekly subcutaneous semaglutide over 9 weeks in adults with AUD evaluated alcohol consumption and craving; semaglutide was generally well tolerated (decreased appetite, GI symptoms, headache), participants lost 5% body weight, and no serious adverse events occurred. Current guidance: consider semaglutide only after failed trials of the FDA-approved medications, with careful comorbidity screening. Phase 3 trials are underway; high cost may limit adoption.

Behavioural treatment components standardised. The most effective AUD interventions comprise assessment, personalised feedback, motivational interviewing, goal setting, planning and review of homework, problem-solving skills, and relapse prevention and management.

Psychedelic-assisted therapy — investigational. Hallucinogenic (psilocybin) and dissociative (ketamine) agents combined with psychotherapy may reduce heavy drinking days and increase abstinent days, but more research is needed.

De-addiction = a multistage process integrating physical, psychological and social interventions, run concurrently, not consecutively.

Five steps: identify → motivate → detoxify → treat comorbidity → rehabilitate.

Safe withdrawal takes weeks to months in the elderly vs days to weeks in the young.

Elderly withdrawal is complicated by confusion/delirium far more often; rapid detoxification risks convulsions.

Thiamine before glucose, always.

Inpatient detoxification if severe dependency or rapid withdrawal is required.

Cross-tolerance between alcohol and benzodiazepines — exploited for detoxification, dangerous if ignored.

15% of over-65s in alcohol detoxification are dependent on a second drug (hypnotic, anxiolytic or analgesic).

Confrontational programmes halve one-year abstinence rates in the elderly — use low-confrontation, self-esteem-promoting, age-specific groups.

Outcomes at 6 months are no different from younger patients — never be nihilistic.

Naltrexone (± XR) and acamprosate are now the preferred pharmacotherapy; disulfiram is hazardous in the elderly.

Semaglutide = the emerging third-line option after approved drugs fail.

Only ~2% of people with AUD receive pharmacotherapy — the treatment gap is the headline statistic.